Based in Montreal, Ocythera is developing a new generation of non-retinoid therapies for rare bone diseases. Originating from pivotal research made at Queen’s University and drug discovery from adMare BioInnovations, the company is advancing highly selective compounds with an improved safety and efficacy profile, targeting one of the enzymes involved in the metabolism of retinoic acids. To learn more about Ocythera, visit ocythera.com.